EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSSPAG00000021675
Gene Symbol: PIK3R5
3 Cross references
200 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSSPAG00000013173
Gene Symbol: PLA2G7
3 Cross references
203 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSSPAG00000005516
Gene Symbol: GART
3 Cross references
246 Possible Orthologues:

Plasminogen

Ensembl ID : ENSSPAG00000002909
Gene Symbol: PLG
3 Cross references
251 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSSPAG00000007540
Gene Symbol: PLAT
3 Cross references
205 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSSPAG00000017268
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSSPAG00000015026
Gene Symbol: PDGFRA
3 Cross references
203 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSSPAG00000000943
Gene Symbol: PDGFRB
3 Cross references
198 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSSPAG00000017822
Gene Symbol: PDGFB
2 Cross references
190 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSSPAG00000015435
Gene Symbol: PLK1
4 Cross references
188 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSSPAG00000012088
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSSPAG00000019074
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).